The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades

Since the first clinical application of analgesia following spinal anticholinesterase by 1940's, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 μg, due to side-effects. Conversely, epidural neostigmine has...

Descripción completa

Detalles Bibliográficos
Autor principal: Lauretti, Gabriela Rocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279354/
https://www.ncbi.nlm.nih.gov/pubmed/25558203
http://dx.doi.org/10.4103/1658-354X.146319
_version_ 1782350671500017664
author Lauretti, Gabriela Rocha
author_facet Lauretti, Gabriela Rocha
author_sort Lauretti, Gabriela Rocha
collection PubMed
description Since the first clinical application of analgesia following spinal anticholinesterase by 1940's, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 μg, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects.
format Online
Article
Text
id pubmed-4279354
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42793542015-01-02 The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades Lauretti, Gabriela Rocha Saudi J Anaesth Review Article Since the first clinical application of analgesia following spinal anticholinesterase by 1940's, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 μg, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4279354/ /pubmed/25558203 http://dx.doi.org/10.4103/1658-354X.146319 Text en Copyright: © Saudi Journal of Anaesthesia http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lauretti, Gabriela Rocha
The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title_full The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title_fullStr The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title_full_unstemmed The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title_short The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
title_sort evolution of spinal/epidural neostigmine in clinical application: thoughts after two decades
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279354/
https://www.ncbi.nlm.nih.gov/pubmed/25558203
http://dx.doi.org/10.4103/1658-354X.146319
work_keys_str_mv AT laurettigabrielarocha theevolutionofspinalepiduralneostigmineinclinicalapplicationthoughtsaftertwodecades
AT laurettigabrielarocha evolutionofspinalepiduralneostigmineinclinicalapplicationthoughtsaftertwodecades

Ejemplares similares